In this week’s edition of InnovationRx, we look at French healthtech Doctolib’s potential large secondary round, Alice ...

Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Pfizer, which makes the shot, is fighting a lawsuit from more than 1,000 women who claim the company knew about the risk of meningiomas but failed to warn patients. Meanwhile, former Vice President ...

Pfizer faces a lawsuit in which women allege the drugmaker failed to warn them about the risks of meningioma associated with ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...

Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...

Oral GnRH antagonists like Myfembree, Yselty, and Oriahnn now lead uterine fibroid treatment, offering high efficacy in ...

Morgan Stanley (MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...